SCHEMBL3630713

SCHEMBL3630713

N#Cc1ccc(Br)cc1N[C@H]1CCOC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 6/20 0.41
PDE1C Q14123 5/20 0.41
PDE1A P54750 3/20 0.41
PRKCQ Q04759 1/20 0.36
PRKCD Q05655 1/20 0.36
BCL6 P41182 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAOA P21397 2/20 0.34
MAOB P27338 2/20 0.34
KDM1A O60341 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
CTSK P43235 1/20 0.34
FGFR4 P22455 1/20 0.34
CD38 P28907 1/20 0.32
NSD2 O96028 1/20 0.32
JAK2 O60674 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3630716 1.00 PDE1B (0.41) PDE1BPDE1CPDE1APRKCQPRKCD
SCHEMBL18340326 0.80 JAK2 (0.40) PDE1BPDE1CPDE1APRKCQPRKCD
SCHEMBL495783 0.80 MEN1 (0.47) MEN1KMT2AL3MBTL1MAOAMAOB
SCHEMBL4581365 0.77 PRKCQ (0.48) PRKCQPRKCDMEN1KMT2AL3MBTL1
SCHEMBL12820379 0.77 PRKCQ (0.48) PRKCQPRKCDMEN1KMT2AL3MBTL1
SCHEMBL3630162 0.76 BCL6 (0.36) PDE1BPDE1CPDE1ABCL6CTSK
SCHEMBL3630158 0.76 BCL6 (0.36) PDE1BPDE1CPDE1ABCL6CTSK
SCHEMBL23177187 0.75 AAK1 (0.41) PDE1BPDE1CPDE1AMAOAMAOB
SCHEMBL23177336 0.75 AAK1 (0.41) PDE1BPDE1CPDE1AMAOAMAOB
SCHEMBL30980951 0.75 AAK1 (0.41) PDE1BPDE1CPDE1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012126084-A1 HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE IΝ THE TREATMENT AND PREVENTION OF FUNGAL INFECTIONS PHARMASCIENCE INC. (CA) 2012-09-27 WO disclosed
WO-2011035417-A1 HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES AEGERA THERAPEUTICS INC. (CA) 2011-03-31 WO disclosed
EP-2146967-A2 TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES Serenex, Inc. (US) 2010-01-27 EP disclosed
WO-2008130879-A2 TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES SERENEX, INC. (US) 2008-10-30 WO disclosed
US-20080269193-A1 Tetrahydroindole and Tetrahydroindazole Derivatives SERENEX, INC. 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269193-A1 Tetrahydroindole and Tetrahydroindazole Derivatives HSF1, HSP90AB1, TPH1 PDE1B 3697/4885PDE1C 4240/4885PDE1A 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.